Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1138-41-6

Post Buying Request

1138-41-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1138-41-6 Usage

General Description

Benzoic acid, 4-hydroxy-3-(3-methyl-2-butenyl)-, also known as 4-Hydroxy-3-prenylbenzoic acid, is a natural organic compound found in plants such as sweetgum (Liquidambar styraciflua) and in the resin of the South American tree Hymenaea courbaril. It is a type of phenolic acid with antioxidant properties and is often used in the food industry as a preservative, particularly in acidic products like fruit juices and carbonated drinks. It also has potential applications in the pharmaceutical and cosmetic industries due to its anti-inflammatory and antimicrobial properties. Additionally, it may also have potential as a natural remedy in traditional medicine for various health conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 1138-41-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,3 and 8 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1138-41:
(6*1)+(5*1)+(4*3)+(3*8)+(2*4)+(1*1)=56
56 % 10 = 6
So 1138-41-6 is a valid CAS Registry Number.

1138-41-6Relevant articles and documents

A Monooxygenase from Boreostereum vibrans Catalyzes Oxidative Decarboxylation in a Divergent Vibralactone Biosynthesis Pathway

Yang, Yan-Long,Zhou, Hui,Du, Gang,Feng, Ke-Na,Feng, Tao,Fu, Xiao-Li,Liu, Ji-Kai,Zeng, Ying

, p. 5463 - 5466 (2016)

The oxidative decarboxylation of prenyl 4-hydroxybenzoate to prenylhydroquinone has been frequently proposed for the biosynthesis of prenylated (hydro)quinone derivates (sometimes meroterpenoids), yet no corresponding genes or enzymes have so far been reported. A FAD-binding monooxygenase (VibMO1) was identified that converts prenyl 4-hydroxybenzoate into prenylhydroquinone and is likely involved in the biosynthesis of vibralactones and other meroterpenoids in the basidiomycete Boreostereum vibrans. Feeding of 3-allyl-4-hydroxybenzylalcohol, an analogue of the vibralactone pathway intermediate 3-prenyl-4-hydroxybenzylalcohol, generated 20 analogues with different scaffolds. This demonstrated divergent pathways to skeletally distinct compounds initiating from a single precursor, thus providing the first insight into a novel biosynthetic pathway for 3-substituted γ-butyrolactones from a shikimate origin.

Discovery of a Dual Function Cytochrome P450 that Catalyzes Enyne Formation in Cyclohexanoid Terpenoid Biosynthesis

Chein, Rong-Jie,Chen, Yu-Rong,Liang, Suh-Yuen,Lin, Chun-Hung,Lin, Hsiao-Ching,Naresh, Annavareddi

supporting information, p. 13537 - 13541 (2020/06/05)

The 1,3-enyne moiety is commonly found in cyclohexanoid natural products produced by endophytic and plant pathogenic fungi. Asperpentyn (1) is a 1,3-enyne-containing cyclohexanoid terpenoid isolated from Aspergillus and Pestalotiopsis. The genetic basis and biochemical mechanism of 1,3-enyne biosynthesis in 1, and other natural products containing this motif, has remained enigmatic despite their potential ecological roles. Identified here is the biosynthetic gene cluster and characterization of two crucial enzymes in the biosynthesis of 1. A P450 monooxygenase that has a dual function, to first catalyze dehydrogenation of the prenyl chain to generate a cis-diene intermediate and then serve as an acetylenase to yield an alkyne moiety, and thus the 1,3-enyne, was discovered. A UbiA prenyltransferase was also characterized and it is unusual in that it favors transferring a five-carbon prenyl chain, rather than a polyprenyl chain, to a p-hydroxybenzoic acid acceptor.

NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE

-

, (2011/04/24)

Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1138-41-6